• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性胸腔积液管理的当代最佳实践。

Contemporary best practice in the management of malignant pleural effusion.

机构信息

Division of Pulmonology, Department of Medicine, Stellenbosch University and Tygerberg Academic Hospital, PO Box 241, Cape Town, 8000, South Africa.

Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa.

出版信息

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618785098. doi: 10.1177/1753466618785098.

DOI:10.1177/1753466618785098
PMID:29952251
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6048656/
Abstract

Malignant pleural effusion (MPE) affects more than 1 million people globally. There is a dearth of evidence on the therapeutic approach to MPE, and not surprisingly a high degree of variability in the management thereof. We aimed to provide practicing clinicians with an overview of the current evidence on the management of MPE, preferentially focusing on studies that report patient-related outcomes rather than pleurodesis alone, and to provide guidance on how to approach individual cases. A pleural intervention for MPE will perforce be palliative in nature. A therapeutic thoracentesis provides immediate relief for most. It can be repeated, especially in patients with a slow rate of recurrence and a short anticipated survival. Definitive interventions, individualized according the patient's wishes, performance status, prognosis and other considerations (including the ability of the lung to expand) should be offered to the remainder of patients. Chemical pleurodesis (achieved via intercostal drain or pleuroscopy) and indwelling pleural catheter (IPC) have equal impact on patient-based outcomes, although patients treated with IPC spend less time in hospital and have less need for repeat pleural drainage interventions. Talc slurry via IPC is an attractive recently validated option for patients who do not have a nonexpandable lung.

摘要

恶性胸腔积液(MPE)影响着全球超过 100 万人。目前针对 MPE 的治疗方法的证据不足,管理方法也存在很大差异,这并不奇怪。我们的目的是为临床医生提供 MPE 管理方面的最新证据概述,优先关注报告患者相关结局的研究,而不仅仅是单纯的胸膜固定术,并就如何处理个别病例提供指导。针对 MPE 的胸膜介入治疗必然是姑息性的。大多数情况下,治疗性胸腔穿刺术可立即缓解症状。对于复发率较慢且预期生存时间较短的患者,可以重复进行胸腔穿刺术。应根据患者的意愿、身体状况、预后和其他因素(包括肺扩张能力),为其余患者提供个体化的确定性干预措施。化学性胸膜固定术(通过肋间引流或胸腔镜实现)和留置胸腔导管(IPC)对基于患者的结局具有同等影响,尽管接受 IPC 治疗的患者在医院的住院时间更短,需要重复胸腔引流干预的次数也更少。对于没有可扩张肺的患者,通过 IPC 注入滑石粉混悬液是一种最近得到验证的有吸引力的选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a73f/6048656/a2c369a1c393/10.1177_1753466618785098-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a73f/6048656/a2c369a1c393/10.1177_1753466618785098-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a73f/6048656/a2c369a1c393/10.1177_1753466618785098-fig1.jpg

相似文献

1
Contemporary best practice in the management of malignant pleural effusion.恶性胸腔积液管理的当代最佳实践。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618785098. doi: 10.1177/1753466618785098.
2
ERS/EACTS statement on the management of malignant pleural effusions.ERS/EACTS 声明:恶性胸腔积液的管理
Eur Respir J. 2018 Jul 27;52(1). doi: 10.1183/13993003.00349-2018. Print 2018 Jul.
3
Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline.恶性胸腔积液的处理。美国胸科学会/胸外科学会/胸外科医师学会临床实践指南官方版。
Am J Respir Crit Care Med. 2018 Oct 1;198(7):839-849. doi: 10.1164/rccm.201807-1415ST.
4
Recent developments in pleurodesis for malignant pleural disease.恶性胸膜疾病胸膜固定术的最新进展
Clin Respir J. 2018 Oct;12(10):2463-2468. doi: 10.1111/crj.12958.
5
[Chinese expert consensus on treatment of malignant pleural effusion (2023 Edition)].《恶性胸腔积液治疗中国专家共识(2023年版)》
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Dec 12;46(12):1189-1203. doi: 10.3760/cma.j.cn112147-20230902-00126.
6
Australasian Malignant PLeural Effusion (AMPLE)-3 trial: study protocol for a multi-centre randomised study comparing indwelling pleural catheter (±talc pleurodesis) versus video-assisted thoracoscopic surgery for management of malignant pleural effusion.澳大利亚恶性胸腔积液(AMPLE)-3 试验:一项多中心随机研究的研究方案,比较留置胸腔导管(±滑石粉胸膜固定术)与电视辅助胸腔镜手术治疗恶性胸腔积液。
Trials. 2022 Jun 27;23(1):530. doi: 10.1186/s13063-022-06405-7.
7
Update on the diagnosis and management of malignant pleural effusions.恶性胸腔积液的诊断与管理进展
Respir Med. 2022 May;196:106802. doi: 10.1016/j.rmed.2022.106802. Epub 2022 Mar 9.
8
OPTIMUM: a protocol for a multicentre randomised controlled trial comparing Out Patient Talc slurry via Indwelling pleural catheter for Malignant pleural effusion vs Usual inpatient Management.OPTIMUM:一项多中心随机对照试验方案,比较经留置胸膜导管的门诊滑石粉悬液治疗恶性胸腔积液与常规住院治疗。
BMJ Open. 2016 Oct 18;6(10):e012795. doi: 10.1136/bmjopen-2016-012795.
9
Interventional therapies for malignant pleural effusions: the present and the future.恶性胸腔积液的介入治疗:现状与未来
Respirology. 2014 Aug;19(6):809-22. doi: 10.1111/resp.12328. Epub 2014 Jun 19.
10
Malignant pleural effusion in the palliative care setting.姑息治疗环境中的恶性胸腔积液
Int J Palliat Nurs. 2013 Jul;19(7):320, 322-5.

引用本文的文献

1
Driver mutations and malignant pleural effusion in non-small cell lung cancer.非小细胞肺癌中的驱动基因突变与恶性胸腔积液
BMC Med Genomics. 2025 Jul 1;18(1):112. doi: 10.1186/s12920-025-02180-x.
2
Clinical and Molecular Features of Malignant Pleural Effusion in Non-Small Cell Lung Cancer (NSCLC) of a Caucasian Population.高加索人群中非小细胞肺癌(NSCLC)恶性胸腔积液的临床和分子特征。
Medicina (Kaunas). 2024 Nov 3;60(11):1804. doi: 10.3390/medicina60111804.
3
Comparison of outcomes of surgical and other invasive treatment modalities for malignant pleural effusion in patients with pleural carcinomatosis.

本文引用的文献

1
Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion.门诊经留置胸腔导管滑石粉给药治疗恶性胸腔积液。
N Engl J Med. 2018 Apr 5;378(14):1313-1322. doi: 10.1056/NEJMoa1716883.
2
Pleural Disease.胸膜疾病
N Engl J Med. 2018 Feb 22;378(8):740-751. doi: 10.1056/NEJMra1403503.
3
Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.留置胸膜导管与滑石粉胸膜固定术对恶性胸腔积液患者住院天数的影响:AMPLE随机临床试验
胸膜转移癌患者恶性胸腔积液的手术及其他侵入性治疗方式的疗效比较。
J Thorac Dis. 2024 Feb 29;16(2):960-972. doi: 10.21037/jtd-23-1247. Epub 2024 Feb 23.
4
Malignant pleural disease.恶性胸膜疾病
Breathe (Sheff). 2023 Dec;19(4):230145. doi: 10.1183/20734735.0145-2023. Epub 2024 Feb 13.
5
A practical approach to the diagnosis and management of malignant pleural effusions in resource-constrained settings.资源受限环境下恶性胸腔积液诊断与管理的实用方法
Breathe (Sheff). 2023 Dec;19(4):230140. doi: 10.1183/20734735.0140-2023. Epub 2023 Dec 19.
6
Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in EGFR-mutated lung cancer.基于单细胞 RNA 测序的 EGFR 突变型肺癌胸膜微环境龛和肿瘤转移的特征分析。
Theranostics. 2023 Aug 6;13(13):4412-4429. doi: 10.7150/thno.85084. eCollection 2023.
7
S100A9 Regulated M1/M2 Macrophage Polarization in Interleukin-10-Induced Promotion of Malignant Pleural Effusion.S100A9 调控白细胞介素-10 诱导的恶性胸腔积液中 M1/M2 型巨噬细胞极化
J Immunol Res. 2023 Jul 25;2023:3473464. doi: 10.1155/2023/3473464. eCollection 2023.
8
Malignant pleural effusion diagnosis and therapy.恶性胸腔积液的诊断与治疗。
Open Life Sci. 2023 Feb 28;18(1):20220575. doi: 10.1515/biol-2022-0575. eCollection 2023.
9
Current status of and progress in the treatment of malignant pleural effusion of lung cancer.肺癌恶性胸腔积液的治疗现状与进展
Front Oncol. 2023 Jan 20;12:961440. doi: 10.3389/fonc.2022.961440. eCollection 2022.
10
Platelet-Rich Plasma for Pleurodesis: An Experimental Study in Rabbits.富血小板血浆用于胸膜固定术:兔的实验研究。
Medicina (Kaunas). 2022 Dec 15;58(12):1842. doi: 10.3390/medicina58121842.
JAMA. 2017 Nov 21;318(19):1903-1912. doi: 10.1001/jama.2017.17426.
4
Malignant Pleural Effusions: Mistletoe Spray Instead of Talc Poudrage?恶性胸腔积液:用槲寄生喷雾替代滑石粉喷洒?
Respiration. 2018;95(3):143-144. doi: 10.1159/000482010. Epub 2017 Nov 7.
5
Pleurodesis Using Mistletoe Extract Delivered via a Spray Catheter during Semirigid Pleuroscopy for Managing Symptomatic Malignant Pleural Effusion.经半刚性胸腔镜检查采用喷雾导管给予槲寄生提取物行胸膜固定术治疗恶性胸腔积液所致症状性胸腔积液。
Respiration. 2018;95(3):177-181. doi: 10.1159/000481869. Epub 2017 Nov 7.
6
Surgical and non-surgical management of malignant pleural effusions.恶性胸腔积液的外科和非外科处理。
Expert Rev Respir Med. 2018 Jan;12(1):15-26. doi: 10.1080/17476348.2018.1398085. Epub 2017 Nov 9.
7
Quality Gaps and Comparative Effectiveness of Management Strategies for Recurrent Malignant Pleural Effusions.复发性恶性胸腔积液管理策略的质量差距和比较效果。
Chest. 2018 Feb;153(2):438-452. doi: 10.1016/j.chest.2017.08.026. Epub 2017 Aug 31.
8
A Novel Drug-Eluting Indwelling Pleural Catheter for the Management of Malignant Effusions.一种用于治疗恶性胸腔积液的新型药物洗脱留置胸膜导管
Am J Respir Crit Care Med. 2018 Jan 1;197(1):136-138. doi: 10.1164/rccm.201701-0097LE.
9
Feasibility of objectively measured physical activity and sedentary behavior in patients with malignant pleural effusion.客观测量恶性胸腔积液患者身体活动和久坐行为的可行性。
Support Care Cancer. 2017 Oct;25(10):3133-3141. doi: 10.1007/s00520-017-3721-9. Epub 2017 Apr 28.
10
Current practices in the management of malignant pleural effusions: a survey among members of the European Society of Thoracic Surgeons.恶性胸腔积液的当前管理实践:欧洲胸外科医师协会成员的一项调查
Interact Cardiovasc Thorac Surg. 2017 Mar 1;24(3):414-417. doi: 10.1093/icvts/ivw373.